The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‑1 antibody suppresses the progression of non‑small cell lung cancer tumors by enhancing immunocompetence

Gui,Huan; Nie,Yujie; Yuan,Haohua; Jing,Qianyu; Li,Linzhao; Zhu,Lan; Chen,Shuanghui; Wang,Mengjiao; Wan,Quan; Lv,Hang; Nie,Yingjie; Zhang,Xiangyan

doi:10.3892/or.2024.8808

The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‑1 antibody suppresses the progression of non‑small cell lung cancer tumors by enhancing immunocompetence

Authors:
- Huan Gui
- Yujie Nie
- Haohua Yuan
- Qianyu Jing
- Linzhao Li
- Lan Zhu
- Shuanghui Chen
- Mengjiao Wang
- Quan Wan
- Hang Lv
- Yingjie Nie
- Xiangyan Zhang
View Affiliations

Affiliations: School of Medicine, Guizhou University, Guiyang, Guizhou 550025, P.R. China, NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guiyang, Guizhou 550002, P.R. China
Published online on: September 6, 2024 https://doi.org/10.3892/or.2024.8808
Article Number: 149
Copyright: © Gui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is increasingly recognized as a leading cause of cancer‑related mortality. Immunotherapy has emerged as a promising therapeutic approach for lung cancer, particularly non‑small cell lung cancer (NSCLC). Nonetheless, the response rate to programmed cell death 1 (PD‑1) inhibitors remains less than optimal. It has been suggested that protein tyrosine phosphatase 1B (PTP1B) plays a crucial role in the development and progression of cancer by facilitating T cell expansion and cytotoxicity. Our previous research demonstrated that the combination of tumor necrosis factor receptor 2 (TNFR2) with immune activity treatments synergistically suppresses tumor growth. This insight led to exploring the efficacy of a combined treatment strategy involving PD‑1 inhibitors, PTP1B inhibitors and TNFR2 antibodies (triple therapy) in NSCLC. In this context, the therapeutic effectiveness of these combination immunotherapies was validated in mouse models with NSCLC by analyzing the expansion and function of immune cells, thereby assessing their impact on tumor growth. The results indicated that inhibiting PTP1B decreases the expression of PD‑L1 and TNFR2 on LLC cells, along with an increase in the proportion of CD4⁺T and CD8⁺T cells. Compared with other treatment groups, the triple therapy significantly reduced tumor volume in mice with NSCLC and extended their survival. Moreover, this combination therapy altered the distribution of myeloid‑derived suppressor cells, dendritic cells, B cells and M1 macrophages, while increasing the proportion of CD8⁺T cells and reducing the proportion of Treg cells in the spleens, lymph nodes, and tumors of NSCLC models. The triple therapy also resulted in a decrease in PD‑L1, PTP1B and TNFR2 expression within NSCLC tumor tissues in mice. Overall, the triple therapy effectively suppressed tumor growth and improved outcomes in mice with NSCLC by modulating immune cell distribution and reducing levels of target immune proteins.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
3	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI
4	Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current therapies and new targeted treatments. Lancet. 389:299–311. 2017. View Article : Google Scholar : PubMed/NCBI
5	Boyero L, Sánchez-Gastaldo A, Alonso M, Noguera-Uclés JF, Molina-Pinelo S and Bernabé-Caro R: Primary and acquired resistance to immunotherapy in lung cancer: Unveiling the mechanisms underlying of immune checkpoint blockade therapy. Cancers (Basel). 12:37292020. View Article : Google Scholar : PubMed/NCBI
6	Wilky BA: Immune checkpoint inhibitors: The linchpins of modern immunotherapy. Immunol Rev. 290:6–23. 2019. View Article : Google Scholar : PubMed/NCBI
7	Patil NS, Nabet BY, Müller S, Koeppen H, Zou W, Giltnane J, Au-Yeung A, Srivats S, Cheng JH, Takahashi C, et al: Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell. 40:289–300.e4. 2022. View Article : Google Scholar : PubMed/NCBI
8	Yi M, Zheng X, Niu M, Zhu S, Ge H and Wu K: Combination strategies with PD-1/PD-L1 blockade: Current advances and future directions. Mol Cancer. 21:282022. View Article : Google Scholar : PubMed/NCBI
9	Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler RD, Lee C, et al: Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: An open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 23:279–291. 2022. View Article : Google Scholar : PubMed/NCBI
10	Zhao B, Zhao H and Zhao J: Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. Ther Adv Med Oncol. 12:17588359209376122020. View Article : Google Scholar : PubMed/NCBI
11	Wang H, Liu F, Chen X, Zhao C, Li X, Zhou C, Hu J, Chu Q and Jiang T: Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases. Exp Hematol Oncol. 12:562023. View Article : Google Scholar : PubMed/NCBI
12	Bakke J and Haj FG: Protein-tyrosine phosphatase 1B substrates and metabolic regulation. Semin Cell Dev Biol. 37:58–65. 2015. View Article : Google Scholar : PubMed/NCBI
13	Bai KH, Zhu MJ, Zhang YY, Li XP, Chen SL, Wang DW and Dai YJ: Multi-omics analyses of tumor-associated immune-infiltrating cells with the novel immune checkpoint protein tyrosine phosphatase 1B (PTP1B) in extracellular matrix of brain-lower-grade-glioma (LGG) and uveal-melanoma (UVM). Front Immunol. 13:10538562022. View Article : Google Scholar : PubMed/NCBI
14	Wilson NS and Huntington ND: Small molecule. Big biology. Dual phosphatase inhibitor enters the immunotherapy fray. Immunol Cell Biol. 102:8–11. 2024. View Article : Google Scholar : PubMed/NCBI
15	Wiede F, Lu KH, Du X, Zeissig MN, Xu R, Goh PK, Xirouchaki CE, Hogarth SJ, Greatorex S, Sek K, et al: PTP1B is an intracellular checkpoint that limits T-cell and CAR T-cell antitumor immunity. Cancer Discov. 12:752–773. 2022. View Article : Google Scholar : PubMed/NCBI
16	Zappasodi R, Merghoub T and Wolchok JD: Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell. 34:6902018. View Article : Google Scholar : PubMed/NCBI
17	Zhu L, Zhang X, Chen X, Yang D, Nie Y, Pan R, Li L, Wang C, Gui H, Chen S, et al: Anti-TNFR2 enhanced the antitumor activity of a new HMGN1/3M-052 stimulated dendritic cell vaccine in a mouse model of colon cancer. Biochem Biophys Res Commun. 653:106–114. 2023. View Article : Google Scholar : PubMed/NCBI
18	Nie Y, Yang D, Trivett A, Han Z, Xin H, Chen X and Oppenheim JJ: Development of a curative therapeutic vaccine (TheraVac) for the treatment of large established tumors. Sci Rep. 7:141862017. View Article : Google Scholar : PubMed/NCBI
19	Zhang X, Lao M, Xu J, Duan Y, Yang H, Li M, Ying H, He L, Sun K, Guo C, et al: Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors. J Immunother Cancer. 10:e0039822022. View Article : Google Scholar : PubMed/NCBI
20	Bourebaba L, Serwotka-Suszczak A, Bourebaba N, Zyzak M and Marycz K: The PTP1B inhibitor trodusquemine (MSI-1436) improves glucose uptake in equine metabolic syndrome affected liver through anti-inflammatory and antifibrotic activity. Int J Inflam. 2023:38030562023.PubMed/NCBI
21	Jing Q, Wan Q, Nie Y, Luo J, Zhang X, Zhu L, Gui H, Li L, Wang C, Chen S, et al: Ansofaxine hydrochloride inhibits tumor growth and enhances Anti-TNFR2 in murine colon cancer model. Front Pharmacol. 14:12860612023. View Article : Google Scholar : PubMed/NCBI
22	Zhang J, Dang F, Ren J and Wei W: Biochemical Aspects of PD-L1 regulation in cancer immunotherapy. Trends Biochem Sci. 43:1014–1032. 2018. View Article : Google Scholar : PubMed/NCBI
23	Sharma B, Xie L, Yang F, Wang W, Zhou Q, Xiang M, Zhou S, Lv W, Jia Y, Pokhrel L, et al: Recent advance on PTP1B inhibitors and their biomedical applications. Eur J Med Chem. 199:1123762020. View Article : Google Scholar : PubMed/NCBI
24	Yuan F, Gao Q, Tang H, Shi J and Zhou Y: Ophiopogonin-B targets PTP1B to inhibit the malignant progression of hepatocellular carcinoma by regulating the PI3K/AKT and AMPK signaling pathways. Mol Med Rep. 25:1222022. View Article : Google Scholar : PubMed/NCBI
25	Bentires-Alj M and Neel BG: Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Res. 67:2420–2424. 2007. View Article : Google Scholar : PubMed/NCBI
26	Ocaranza P, Gaete X, Román R, Morales F, Íñiguez G and Cassorla F: Phosphotyrosine phosphatases in GH-stimulated skin fibroblasts from children with idiopathic short stature. J Pediatr Endocrinol Metab. 26:833–840. 2013. View Article : Google Scholar : PubMed/NCBI
27	Liang S, Tran E, Du X, Dong J, Sudholz H, Chen H, Qu Z, Huntington ND, Babon JJ, Kershaw NJ, et al: A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity. Nat Commun. 14:45242023. View Article : Google Scholar : PubMed/NCBI
28	Penafuerte C, Feldhammer M, Mills JR, Vinette V, Pike KA, Hall A, Migon E, Karsenty G, Pelletier J, Zogopoulos G and Tremblay ML: Downregulation of PTP1B and TC-PTP phosphatases potentiate dendritic cell-based immunotherapy through IL-12/IFNγ signaling. Oncoimmunology. 6:e13211852017. View Article : Google Scholar : PubMed/NCBI
29	Zhu S, Lalani AI, Jin J, Sant'Angelo D, Covey LR, Liu K, Young HA, Ostrand-Rosenberg S and Xie P: The adaptor protein TRAF3 is an immune checkpoint that inhibits myeloid-derived suppressor cell expansion. Front Immunol. 14:11679242023. View Article : Google Scholar : PubMed/NCBI
30	Ubil E, Caskey L, Holtzhausen A, Hunter D, Story C and Earp HS: Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response. J Clin Invest. 128:2356–2369. 2018. View Article : Google Scholar : PubMed/NCBI
31	Lu S, Sun Z, Hu W, Yin S, Zhao C and Hu H: PD-L1 positively regulates MET phosphorylation through inhibiting PTP1B. Cancer Sci. 112:1878–1887. 2021. View Article : Google Scholar : PubMed/NCBI
32	Gao S, Gang J, Yu M, Xin G and Tan H: Computational analysis for identification of early diagnostic biomarkers and prognostic biomarkers of liver cancer based on GEO and TCGA databases and studies on pathways and biological functions affecting the survival time of liver cancer. BMC Cancer. 21:7912021. View Article : Google Scholar : PubMed/NCBI
33	Gao S, Tan H and Gang J: Inhibition of hepatocellular carcinoma cell proliferation through regulation of the Cell Cycle, AGE-RAGE, and Leptin signaling pathways by a compound formulation comprised of andrographolide, wogonin, and oroxylin A derived from Andrographis Paniculata(Burm.f.) Nees. J Ethnopharmacol. 329:1180012024. View Article : Google Scholar : PubMed/NCBI
34	Wu R, Wang C, Li Z, Xiao J, Li C, Wang X, Kong P, Cao J, Huang F, Li Z, et al: SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA. J Immunother Cancer. 8:e0010372020. View Article : Google Scholar : PubMed/NCBI
35	Qu Y, Wang X, Bai S, Niu L, Zhao G, Yao Y, Li B and Li H: The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer. Int J Cancer. 150:1373–1391. 2022. View Article : Google Scholar : PubMed/NCBI
36	Gao S, Tan H and Li D: Oridonin suppresses gastric cancer SGC-7901 cell proliferation by targeting the TNF-alpha/androgen receptor/TGF-beta signalling pathway axis. J Cell Mol Med. 27:2661–2674. 2023. View Article : Google Scholar : PubMed/NCBI
37	Medler J, Kucka K and Wajant H: Tumor necrosis factor receptor 2 (TNFR2): An emerging target in cancer therapy. Cancers (Basel). 14:26032022. View Article : Google Scholar : PubMed/NCBI
38	Berdnikovs S, Pavlov VI, Abdala-Valencia H, McCary CA, Klumpp DJ, Tremblay ML and Cook-Mills JM: PTP1B deficiency exacerbates inflammation and accelerates leukocyte trafficking in vivo. J Immunol. 188:874–884. 2012. View Article : Google Scholar : PubMed/NCBI
39	Zhang J, Li L, Li J, Liu Y, Zhang CY, Zhang Y and Zen K: Protein tyrosine phosphatase 1B impairs diabetic wound healing through vascular endothelial growth factor receptor 2 dephosphorylation. Arterioscler Thromb Vasc Biol. 35:163–174. 2015. View Article : Google Scholar : PubMed/NCBI
40	Mabeta P and Steenkamp V: The VEGF/VEGFR axis revisited: Implications for cancer therapy. Int J Mol Sci. 23:155852022. View Article : Google Scholar : PubMed/NCBI